ORAL ANTICOAGULATION AND LEFT ATRIAL APPENDAGE OCCLUSION DEVICES FOR CARDIOEMBOLIC PREVENTION OF ARRHYTHMIAS IN CHRONIC KIDNEY DISEASE AND DIALYSIS SURVEY
PLEASE SELECT THE MOST APPROPRIATE RESPONSE 1. Have you ever treated a patient with a left atrial appendage occlusion device for the prevention of stroke (e.g. a Watchman device)?
Left atrial appendage occlusion (LAAO) devices occlude the left atrial appendage to decrease the chance of clot formation and subsequent embolisms that cause strokes and systemic embolism. Once the LAAO device is inserted via a percutaneous procedure, it endothelializes and patients may stop their anticoagulation. LAAO devices may therefore be useful to avoid oral anticoagulation in patients at high risk of bleeding or with contraindications to oral anticoagulants.
PROTECT-AF was a multicenter non-inferiority randomized controlled trial of 707 adults with non-valvular atrial fibrillation, CHADS2 score of 1 or more, and normal renal function comparing WATCHMAN, a LAAO device, to warfarin. The WATCHMAN device was considered non-inferior to warfarin in terms of the primary composite endpoint of stroke, cardiovascular death and systemic embolism (3.0 per 100 patient years in WATCHMAN vs 4.9 per 100 patient years with warfarin, RR 0.62 95% C.I. 0.35-1.25).
The WATCHMAN was complicated by a 5.61% chance of an adverse event around the time of the LAAO procedure including pericardial effusion (4.8%), major bleeding (3.5%), procedure-related ischemic stroke (1.1%) and device embolization (0.6%) in follow-up. However, further follow-up analysis at a mean 3.0 (1.6) years met criteria for superiority with adverse events no longer being statistically significantly different between groups. Furthermore, as experience with WATCHMAN has increased, device/procedure-related complications have decreased to 3.6% through 30 days.
A patient level meta-analysis including PROTECT-AF and another randomized controlled trial comparing the WATCHMAN to warfarin (PREVAIL) and their respective registries including 2406 patients and 5931 patient-years of follow-up showed that the WATCHMAN device was associated with significantly less hemorrhagic strokes HR 0.22 P=0.004 and non-procedural bleeding HR 0.51 (0.006) with no difference in all-cause stroke or systemic embolism (HR 1.02) P=0.94 but an increase in ischemic strokes HR 1.95 P=0.05 due to procedural risks.
2. Have you ever treated a patient on dialysis with apixaban?
Apixaban is a direct factor Xa inhibitor that decreases the risk of stroke and systemic embolism. In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOLE) study, a randomized, double-blind, non-inferiority trial of 18201 patients with non-valvular atrial fibrillation and CHADS2 of 1 of more, apixaban 5mg orally twice daily compared to warfarin (target INR 2.0 to 3.0) significantly decreased the risk of stroke and systemic embolism with a hazard ratio of 0.79 (95% C.I. 0.66-0.95) while also significantly decreasing the risk of major bleeding with a hazard ratio of 0.69 (95% C.I. 0.60-0.80). Results were consistent in 16.6% of participants with eGFR<50ml/min/1.73m 2 including only a very few with eGFR<30ml/min/1.73m 2 . A pharmacokinetic study suggests that dialysis patients exposed to the same dose of apixaban appear to have 30% higher levels of the drug and that dialyzability is negligible. No high quality clinical outcome data exists.
3. You are caring for a 65 year old Caucasian male treated with intermittent hemodialysis with nonvalvular atrial fibrillation and hypertension but no congestive heart failure, diabetes, stroke, liver disease, previous major bleeding, antiplatelet agents/non-steroidal anti-inflammatory drugs or alcohol use. a) On a scale of 1-8 with 1 being the least and 8 being the most, how much do you value avoiding a stroke in this patient? 
